Clinical Trial Results:
A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib candidate vaccine compared to the Zilbrix/Hib and Poliorix vaccines administered concomitantly, when administered as a single booster dose to poliovirus vaccine-primed healthy toddlers aged 12-24 months.
Summary
|
|
EudraCT number |
2016-000645-31 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
02 Sep 2010
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
18 May 2018
|
First version publication date |
24 Aug 2016
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
113264
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01106092 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l’Institut 89, Rixensart, Belgium, B-1330
|
||
Public contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, +44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, +44 2089904466, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Dec 2010
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
02 Sep 2010
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
02 Sep 2010
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
•To demonstrate the non-inferiority of GSK Biologicals’ DTPw-HBV-IPV(3 doses)/Hib vaccine compared to Poliorix co-administered with Zilbrix/Hib,
-(full dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the geometric mean (GM) of the individual ratios (post- over pre-booster titres) for anti-poliovirus antibodies (Abs), 1 month after booster vaccination
-(1/2 dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the GM of the individual ratios (post- over pre-booster titres) for anti-poliovirus abs, 1 month after booster vaccination
-(1/3 dose): in terms of seroprotection rates to the 3 poliovirus types and to demonstrate that the formulation induces at least a 2-fold increase in the GM of the individual ratios (post- over pre-booster titres) for anti-poliovirus Abs, 1month after booster vaccination.
|
||
Protection of trial subjects |
The vaccinees were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
13 May 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Philippines: 312
|
||
Worldwide total number of subjects |
312
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
312
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | |||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||
Roles blinded |
Investigator, Subject | |||||||||||||||||||||||||
Blinding implementation details |
The study was conducted in a partially double blind manner:
• The study was double blind [i.e. the investigator and parent(s)/LAR(s) of the subjects were unaware of the treatment administered] for the three groups receiving the three different DTPw-HBV-IPV/Hib formulations (Form groups).
• The study was open-label with respect to the Control Group as subjects in this group received two injections.
|
|||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||
Arm title
|
GSK2036874A Group 1 | |||||||||||||||||||||||||
Arm description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
GSK2036874A
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
DTPw-HBV-IPV/Hib
|
|||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||
Dosage and administration details |
Subjects received one dose of the vaccine (formulation 1) in the anterolateral region of the left thigh, at Day 0.
|
|||||||||||||||||||||||||
Arm title
|
GSK2036874A Group 2 | |||||||||||||||||||||||||
Arm description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
GSK2036874A
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
DTPw-HBV-IPV/Hib
|
|||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||
Dosage and administration details |
Subjects received one dose of the vaccine (formulation 2) in the anterolateral region of the left thigh, at Day 0.
|
|||||||||||||||||||||||||
Arm title
|
GSK2036874A Group 3 | |||||||||||||||||||||||||
Arm description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||
Investigational medicinal product name |
GSK2036874A
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
DTPw-HBV-IPV/Hib
|
|||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||
Dosage and administration details |
Subjects received one dose of the vaccine (formulation 3) in the anterolateral region of the left thigh, at Day 0.
|
|||||||||||||||||||||||||
Arm title
|
Zilbrix/HIB/Poliorix Group | |||||||||||||||||||||||||
Arm description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib and Poliorix vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively. | |||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||
Investigational medicinal product name |
Zilbrix/Hib
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
DTPw-HBV/Hib Kft.
|
|||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||
Dosage and administration details |
Subjects received one dose of the vaccine in the anterolateral region of the left thigh, at Day 0.
|
|||||||||||||||||||||||||
Investigational medicinal product name |
Poliorix
|
|||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||
Other name |
IPV
|
|||||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
|||||||||||||||||||||||||
Dosage and administration details |
Subjects received one dose of the vaccine in the anterolateral region of the right thigh, at Day 0.
|
|||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib and Poliorix vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
GSK2036874A Group 1
|
||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||
Reporting group title |
GSK2036874A Group 2
|
||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||
Reporting group title |
GSK2036874A Group 3
|
||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0. | ||
Reporting group title |
Zilbrix/HIB/Poliorix Group
|
||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib and Poliorix vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively. |
|
|||||||||||||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS SEROPROTECTED AGAINST ANTI-POLIOVIRUS (ANTI-POLIO) TYPES 1, 2 AND 3. | ||||||||||||||||||||||||||||||
End point description |
Seroprotection was defined as anti-polio types 1, 2 and 3 antibody titres ≥ 8 effective dose (ED50), for 50% of vaccinated subjects.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 1 (POST)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 1 (F1) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 1) compared to Poliorix™ vaccine co-administered with Zilbrix™/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 1 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
Zilbrix/HIB/Poliorix Group v GSK2036874A Group 1
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [1] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.72 | ||||||||||||||||||||||||||||||
Notes [1] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 1] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 1 (F2) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 2) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 1 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
Zilbrix/HIB/Poliorix Group v GSK2036874A Group 2
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
1.28
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-3.53 | ||||||||||||||||||||||||||||||
upper limit |
6.94 | ||||||||||||||||||||||||||||||
Notes [2] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 2] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 1 (F3) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 3) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 1 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 3 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [3] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.72 | ||||||||||||||||||||||||||||||
Notes [3] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 3] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 2 (F1) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 1) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 2 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 1 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [4] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.78 | ||||||||||||||||||||||||||||||
Notes [4] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 1] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 2 (F2) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 2) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 2 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 2 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [5] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.72 | ||||||||||||||||||||||||||||||
Notes [5] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 2] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 2 (F3) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 3) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 2 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 3 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [6] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.72 | ||||||||||||||||||||||||||||||
Notes [6] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 3] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 3 (F1) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 1) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 3 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 1 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [7] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
1.28
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-3.53 | ||||||||||||||||||||||||||||||
upper limit |
6.94 | ||||||||||||||||||||||||||||||
Notes [7] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 1] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 3 (F2) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 2) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 3 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 2 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [8] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
1.28
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-3.53 | ||||||||||||||||||||||||||||||
upper limit |
6.94 | ||||||||||||||||||||||||||||||
Notes [8] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 2] difference in percentage of seroprotected subjects ≤ 10%. |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Difference in SPR rates for anti-polio 3 (F3) | ||||||||||||||||||||||||||||||
Statistical analysis description |
To demonstrate the non-inferiority of GSK2036874A vaccine (Formulation 3) compared to Poliorix™ vaccine co-administered with ZilbrixTM/Hib vaccine, in terms of seroprotection rates to the three poliovirus types and to demonstrate that the formulation induces at least a two-fold increase in the geometric mean of the individual ratios (post- over pre-booster titres) for anti-polio type 3 antibodies, one month after vaccination.
|
||||||||||||||||||||||||||||||
Comparison groups |
GSK2036874A Group 3 v Zilbrix/HIB/Poliorix Group
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
non-inferiority [9] | ||||||||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||||||||
Parameter type |
Difference in seroprotection rate | ||||||||||||||||||||||||||||||
Point estimate |
0
|
||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||
lower limit |
-4.78 | ||||||||||||||||||||||||||||||
upper limit |
4.72 | ||||||||||||||||||||||||||||||
Notes [9] - The upper limit (UL) of the standardized asymptotic 95% confidence interval (CI) on the group [Zilbrix/Hib Group - GSK2036874A Group 3] difference in percentage of seroprotected subjects ≤ 10%. |
|
||||||||||||||||||||||||||||||||||||
End point title |
ANTI-POLIO TYPES 1, 2 AND 3 ANTIBODY TITERS [10] | |||||||||||||||||||||||||||||||||||
End point description |
Antibody titers were presented as geometric mean titers (GMTs).
|
|||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
At Month 1 (POST)
|
|||||||||||||||||||||||||||||||||||
Notes [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||
End point title |
ANTI-POLIO TYPES 1, 2 AND 3 ANTIBODY TITERS [11] | |||||||||||||||||||||||||||||||||||
End point description |
Antibody titers were presented as geometric mean titers (GMTs).
|
|||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE)
|
|||||||||||||||||||||||||||||||||||
Notes [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed. |
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
NUMBER OF SEROCONVERTED SUBJECTS FOR ANTI-POLIO TYPES 1, 2 AND 3 | ||||||||||||||||||||||||||||||
End point description |
Seroconversion was defined as:
For initially seronegative subjects, antibody titre ≥ 8 ED50 one month after the booster dose;
For initially seropositive subjects: antibody titre one month after the booster dose ≥ 4 fold the pre-booster antibody titre;
For subjects with pre-booster antibody titre below the highest dilution tested (reciprocal < 8192 ED50): highest dilution tested one month after the booster dose (reciprocal > 8192 ED50).
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 1 (POST)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS SEROPROTECTED AGAINST ANTI-POLIOVIRUS (ANTI-POLIO) TYPES 1, 2 AND 3. | ||||||||||||||||||||||||||||||
End point description |
Seroprotection was defined as anti-polio types 1, 2 and 3 antibody titres ≥ 8 effective dose (ED50), for 50% of vaccinated subjects.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||
End point title |
NUMBER OF SEROPROTECTED SUBJECTS FOR ANTI-DIPHTHERIA (ANTI-D) AND ANTI-TETANUS (ANTI-T) | |||||||||||||||||||||||||||||||||||
End point description |
Seroprotection was defined as anti-D and anti-T antibody concentration ≥ 0.1 International Units per milliliter (IU/mL).
|
|||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
|||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
End point title |
ANTI-D AND ANTI-T CONCENTRATIONS | ||||||||||||||||||||||||||||||||||||||||
End point description |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
|
||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||
End point title |
NUMBER OF SEROPROTECTED AND SEROPOSITIVE SUBJECTS FOR ANTI-HEPATITIS B (ANTI-HBS) | |||||||||||||||||||||||||||||||||||
End point description |
Seropositivity was defined as anti-HBs antibody concentration ≥ 3.3 milli-international units per milliliter (mIU/mL). Seprotection was defined as anti-HBs antibody concentration ≥ 10 mIU/mL.
Note that percentage of subjects with concentration ≥ 10 mIU/mL was over-estimated due to the use of in-house assay overestimating concentrations between 10-100 mIU/mL. Accordingly GMCs were also overestimated.
A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.
|
|||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
|||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
ANTI-HBS CONCENTRATIONS | ||||||||||||||||||||||||||||||
End point description |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||
End point title |
NUMBER OF SEROPROTECTED SUBJECTS AGAINST ANTI-POLYRIBOSIL-RIBITOL-PHOSPHATE (ANTI-PRP) | |||||||||||||||||||||||||
End point description |
Seprotection was defined as anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (μg/mL).
|
|||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
ANTI-PRP CONCENTRATIONS | ||||||||||||||||||||||||||||||
End point description |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in μg/mL.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||
End point title |
NUMBER OF SEROPOSITIVE SUBJECTS FOR ANTI-BORDETELLA PERTUSSIS (ANTI-BPT) | |||||||||||||||||||||||||
End point description |
Sepositvity was defined as anti-BPT antibody concentration ≥15 ELISA units per milliliter (EL.U/mL).
|
|||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
ANTI-BPT CONCENTRATIONS | ||||||||||||||||||||||||||||||
End point description |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
At Month 0 (PRE) and Month 1 (POST)
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS WITH A BOOSTER RESPONSE FOR ANTI-BPT | ||||||||||||||||||||
End point description |
Booster response defined as:
For initially seronegative subjects, antibody concentration ≥ 15 EL.U/mL one month after the booster dose;
For initially seropositive subjects: antibody concentration one month after the booster dose ≥ 2 fold the pre-booster antibody concentration.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
At Month 1 (POST)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS WITH ANY SOLICITED LOCAL SYMPTOMS | ||||||||||||||||||||||||||||||
End point description |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
During the 8-day (Day 0-Day 7) follow-up period after vaccination.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS WITH ANY UNSOLICITED ADVERSE EVENTS (AES) | ||||||||||||||||||||
End point description |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
During the 31-day (Day 0-Day 30) follow-up period after vaccination
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS WITH SERIOUS ADVERSE EVENTS (SAES) | ||||||||||||||||||||
End point description |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
During the entire study period (from Month 0 to Month 1).
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||
End point title |
NUMBER OF SUBJECTS WITH ANY SOLICITED GENERAL SYMPTOMS | |||||||||||||||||||||||||||||||||||
End point description |
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.
|
|||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||
End point timeframe |
During the 8-day (Day 0-Day 7) follow-up period after vaccination.
|
|||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Solicited local/general symptoms: During the 8-day (Day 0-Day 7) follow-up period after vaccination. Unsolicited AE(s): During the 31-day (Day 0-Day 30) follow-up period after vaccination. SAE(s): During the entire study period (from Month 0 to Month 1)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The number of occurrences reported for solicited symptoms, adverse events, and serious adverse events were not available for posting. The number of subjects affected by each specific event was indicated as the number of occurrences.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GSK2036874A Group 3
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Zilbrix/HIB/Poliorix Group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |